Providing funding up to $135,000
The Incyte Ingenuity Awards aim to support the graft-versus-host disease (GVHD) community by funding novel initiatives that address challenges faced by GVHD patients, caregivers, and healthcare providers.
GVHD is a life-threatening condition that occurs when donor immune cells attack the recipient's organs and tissues after an allogeneic stem cell transplant. There are two major forms of GVHD, acute and chronic, that can affect multiple organ systems, including the skin, digestive tract, and the liver. Both acute and chronic GVHD are associated with significant morbidity and mortality.
Incyte is deeply dedicated to improving the lives of patients with serious diseases, including GVHD. As a part of this commitment, the company is excited to re-open the Incyte Ingenuity Awards application period to continue to foster collaboration amongst key stakeholders to address the specific needs of the GVHD community.
Submit your application by June 12, 2026, for the chance to make a real difference for people living with GVHD.